London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
People have to realise that our current board are not running a company, we are a cash shell, we produce nothing. The existing BoD are likely to all disappear (with the possible exception of Allan Syms) as they are a caretaker board hear to deliver a phoenix from the Ashes of PSL. In the event an RTO is successfully delivered they will likely have an exit in the coming months and the new board of Company X will run the business. The new guys are the ones that need to earn our backing.
Apple, all we want is to be kept informed, they give us snippets of info then go quiet for month's.
They need to prove to us that they are worthy of running the company and deserve our backing so far they haven't done so imo.
We will wait and see.
His actual words were
I'm afraid Tils is not a company I was aware of until now
Tim gave the only sensible answer. Which is actually more positive that simply saying "No, that is definitely NOT the target"
Keeps us guessing with slightly more hope that he simply would not be allowed to divulge the target?
So, "Never heard them"
Of course he has
Our BOD are waste of time.
Would any other BoD do anything different? Seeking an Rto works both ways ie thr target company would scrutinize our viability DD then assess if it fits in with their other possible Rto companies. There must be plenty out there that are better suited to their purposes so maybe Bou are getting a hard time getting the fight company on board? It must take a lot of time consuming behind the scenes talks and 'final decisions' ?
Our suitability could be in question with most targets and months of time over time wasted on reaching final decisions. If we got an Rns for every approach that they have made, no doubt we would all be criticising the BoD at every Rns
It's all too time consuming.
I dont think Tim would be allowed to say either way, it does tie in with the length of time this is taking though as they've been validating stemprintER
Contacted Tim metcalf he's not aware of tizania life sciences.... Unless he's being coy I think your theory jp is just a dream
Doesn't the nature of a cash shell depend on the equity split?
Just because BOU are getting StemPrintER, doesn't mean that they'll get more than, say, 1% of the shares issued??
Question, why would tils let bou have StemPrintER as a merger, its worth billions, about 35% better then the current market lead.
I am in both, so it would be a win win situation, but cannot see this happening.
Our BOD are waste of time.
I am too far down this boring and disappointing road to get excited about imaginary links between BOU and TILS.
Nothing about BOU excites me any more.
Appreciate the heads up JPP. I did watch the proactive video. It sounds like great news for holders there.
I'm keeping an open mind but agree there are some parallels and close coincidences with Tils and the Bould BOD.
It may currently be a dream as siborg quite rightly says - but it could also be very good news for holders here too if it plays out in the way you suggest.
From the company update RNS
"Early detection is proven to increase five year survival rates."
That, IMO, is the clearest pointer we currently have to BOU wanting to list a breast cancer genomics company.
1+1 may well equal 3 until we know different, but this is as excited I've been about BOU's future in many, many months.
So cerrone says they want specialised expertise within the new company to run alongside existing management... I wonder is Syms would be interested in that! Duh!
Absolute dead cert based on the research I've done (and I havent posted even half of it...)
People putting 1 and 1 together and making 3.....until its announced its a dream
I doubt very much Tils will delist from Aim now as they are listing Stem printer in London https://www.proactiveinvestors.co.uk/companies/news/920234/tiziana-life-sciences-to-spin-out-stemprinter-to--maximise-its-value--920234.html
Syms also has a previous history of dealing with spinouts and has been active in other Life Science companies....
"Dr Steve Minter recently founded
NCIMB Ltd, a firm with access to the
unique University of Aberdeen
collection of bacteria, from which a
variety of medicines can be derived.
"Microbial genomics has attracted
less media attention than human
genomics but it is an area of huge
future significance," he remarked.
This is Dr Minter's second major
spinout. In 1992, he started Tepnel
Life Sciences. In 1994, his co-founder
at NCIMB Ltd, Dr Allan Syms, helped
start electronic odour sensor ('e-
noses') firm Osmetech, from
technology first developed at the
University of Manchester Institute of
Science and Technology (UMIST)."
New company will be listed on the full London stock market.. Therefore Antos warrants come into play.
Tiziana announced that StemPrintER is superior tod current market leader oncotype DX very recently, but up until then they had been doing clinical trials and research as far back as March 2019. So over a year to get it to the stage it is at now.
Now surely anyone.. Like Allan Syms... Would have an idea about this sort of thing? Well yes.. Given this little pearl I've just found...
"Putting his skills to good use, Allan moved to Houston, Texas where he spent three years on cancer research, before returning to the UK to set up a lab at Oxford University to study metastasis."
So he's been involved in the UK and USA.. Also has a degree in bio chemistry and a PhD in Cancer Research...set up a lab in Oxford studying metastatis..
Metastatis is... "The development of secondary malignant growths at a distance from a primary site of cancer.".
OH GUESS WHAT STEMPRINTER DOES???
"We envision this in-vitro prognostic test to be used in conjunction with clinical evaluation to identify those patients at increased risk for early and/or late metastasis. StemPrintER is designed to help physicians distinguish ER+/HER2 negative patients"
I'm sorry to beat the drum... But I'm not having this is all coincidental.
Lot of excitement on the TILS board.
Tiziana is listed on both nasdaq and lse/aim but intends to delist in the UK as most volume is in the USA.
This could suggest a nasdaq listing for the new company.. Something we could assist with, given that have suggested moving away from AIM
I'm genuinely excited here...
We'll all rich if this comes off...
i mean the covid test + cancer detection
I was just looking as you posted, ticks all the boxes
Early detection for breast cancer is absolutely crucial.
Stage 1 survival nearly 100%
Stage 2 survival over 95%
Stage 3 survival only 20%
Stage 4 survival only 10%
"The Proposed Transaction , if completed, would comprise the acquisition of a company with a technology and patent portfolio focussed on the early detection of a specific cancer. This is an exciting opportunity to provide a new diagnostic test for cancer that addresses unmet clinical need for early detection. "
Putting 2+2 together here... Tiziana have announced that they plan to spin out their StemPrintER technology into a separately listed company.
Breast Cancer detection.
Fits our most recent update quite well? Based in London and New York.